Daewoong also enter the Vemlidy late-stage drug market

& Chong Kun Dang

Daewoong is 80% of Vemlidy's drug price

Gilead’s hepatitis B treatment

Daewoong Pharmaceutical and Chong Kun Dang will also enter the late-stage drug market for Vemlidy, a chronic hepatitis B treatment previously occupied by Dong-A ST.

 

Daewoong and Chong Kun Dang's products received a month's delay in obtaining approvals, and their benefits were also applied a month later.

 

According to the industry on the 20th, from March 1, Daewoong Pharmaceutical's Vemlidy and Chong Kun Dang's Tenofobell-A will be covered.

 

The two products are salt-modifying drugs of Gilead Sciences' 'Vemlidy'.

 

Daewoong Vemlidy has Tenofovir Alafenamide HemiFumarate as the main ingredient, and Chong Kun Dang Tenofobell-A has Tenofovir Alafenamide Succinate as the main ingredient.

 

These products succeed in the patent challenge through salt change, obtain generics for exclusivity, and are released before generics when the patent has not expired.

 

The drug price calculation standard for salt-changing drugs is 90% of the original.

 

Daewoong Vemliver costs 2828 won, which is 80% of the original Vemlidy (3,535 won).

 

Chong Kun Dang Tenofobell-A costs 2,439 won, which is 69% of the original price.

 

This amount is cheaper than Donga ST Vemlia's 2,474 won, which was previously applied for benefits.

 

Each generic has a different drug pricing strategy, and it is noteworthy how it will affect market sales.

 

Meanwhile, Jeil Pharm's 'Tecavir-D', which was licensed in the same month as Daewoong's and Chong Kun Dang's, is not on the March reimbursement list.

 

Vemlidy is an upgraded version of Gilead's existing hepatitis B treatment 'Viread'.

 

The patent is scheduled to expire on August 15, 2032, and a generic drug with the same ingredient will have to wait another nine years.

 

Last year, Vemlidy's outpatient prescriptions (based on UBIST) were 47.1 billion won, up 18% YoY.